ClinicalTrials.gg
RecruitingNCT06221358PGx-STaRUpdated Oct 29, 2026

Pharmacogenomics of Stimulant Treatment Response

An observational study in Attention-Deficit/ Hyperactivity Disorder (ADHD), sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 6 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Calgary · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 29, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
6 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Canada.

Planned enrollment
4th of 13
400 · median 195
Started
2024
with 5 others
Observational
13 of 85
4 open now
Primary completion
2028-08
later than 13 of 15 live
Registered
76th of 85
by date
Lead sponsor
4 of 85
University of Calgary

Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2024, is one of 13 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 76th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

12 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, or all of them as a file.
02

Study summary

The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).

Read the detailed description

Background: ADHD is a common neurodevelopmental disorder affecting children and adolescents, with psychostimulants, specifically slow-release methylphenidate (e.g., Biphentin®, Concerta®), being a first-line treatment option. However, the response to medications varies significantly among individuals, with some experiencing limited benefits or intolerable side effects. Unlike other areas of psychiatry, ADHD pharmacotherapy lacks genetic markers to guide treatment decisions, resulting in delayed symptom relief and diminished quality of life for patients.

Objectives:

  1. Identifying genomic profiles associated with psychostimulant treatment response and tolerability in children and adolescents with ADHD.
  2. Establishing a research platform for the discovery of new genetic and non-genetic markers of drug treatment outcomes relevant to mental health care in children.
03

Conditions studied

  • Attention-Deficit/ Hyperactivity Disorder (ADHD)

Keywords

  • Children
  • Adolescents
  • ADHD
  • Pharmacogenetics
  • Neurology
  • Psychostimulants
  • Methylphenidate
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
6 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and adolescent with primary diagnosis of ADHD (all types), aged 6-24 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be eligible for participation if all the following are true.

  • Aged 6 - 24 years.
  • Located in Canada.
  • Primary diagnosis of ADHD (all types).
  • Starting Methylphenidate (excluding immediate release forms) treatment.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from participation if any of the following are true.

  • Co-occurring psychotic, bipolar or eating disorders.
  • Significant risk of suicide.
  • An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
  • Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
  • Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study
  • History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Change in ADHD symptom severity

    Strengths and Weaknesses of Attention-Deficit/Hyperactivity Symptoms and Normal Behavior Scale (SWAN) Rating Scale for ADHD. Score range = -90 to +90, with higher scores indicative of worse outcome.

    Time frame: Baseline and 1, 2, 3, and 4 weeks post-baseline

  2. Side effect frequency and severity

    CADDRA ADHD Medication and Side Effect Form

    Time frame: 1, 2, 3, and 4 weeks post-baseline

Secondary outcomes

  1. Methylphenidate/ritalinic acid exposure

    Methylphenidate and ritalinic acid trough plasma levels

    Time frame: 4 weeks post-baseline

  2. Change in working memory

    Sorting Working Memory Test (7 minutes; administered orally and online with research team member). An assessment of working memory. A participant is asked to recall and sequence different stimuli that are presented visually and via audio. Higher scores indicate better outcome.

    Time frame: Baseline and 4 weeks post-baseline

  3. Change in attention

    Dimension Change Card Sort Test (8 minutes; administered online). An assessment of cognitive flexibility and attention. A participant is asked to match a series of picture pairs to a target picture. Higher scores indicate better outcome.

    Time frame: Baseline and 4 weeks post-baseline

  4. Change in inhibitory control

    Flanker Inhibitory Control and Attention Test (7 minutes; administered online). An assessment of inhibitory control and attention. A participant is asked to focus on a particular stimulus while inhibiting attention to the stimuli flanking it. Higher scores indicate better outcome.

    Time frame: Baseline and 4 weeks post-baseline

  5. Change in impulse control

    Stop Signal Task (10 minutes; administered online). An assessment of impulse control. A participant is presented with a target stimulus and are asked to respond to the stimulus as fast as possible. Higher score indicate better outcome.

    Time frame: Baseline and 4 weeks post-baseline

  6. Change in functioning

    Columbia Impairment Scale. Score range 0-52, with higher scores indicative of worse outcome.

    Time frame: Baseline and 4 weeks post-baseline

  7. Change in child quality of life

    Pediatric Quality of Life Inventory (PedsQoL). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better quality of life.

    Time frame: Baseline and 4 weeks post-baseline

  8. Change in carer quality of life

    Care-related Quality of Life instrument (Carer QoL-7D). Utility tariffs for the CarerQol have been developed to calculate a CarerQol-7D utility score from the responses on the seven dimensions, ranging between 0 ('worst imaginable caregiving situation') and 100 ('best imaginable caregiving situation'). Higher utility scores thus reflect better care-related quality of life.

    Time frame: Baseline and 4 weeks post-baseline

07

Study locations

1 of 1 sites recruiting
  • University of Calgary
    Calgary, Alberta, Canada
    Recruiting
    • Madison Heintz, MSW · Contactpsychpgxlab@ucalgary.ca · 5875739747
    • Chad Bousman, MPH, PhD · Principal investigator
    • Kara Murias, MD, PhD · Sub investigator
    • Paul Arnold, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized, individual participant PGx-STaR data will be shared using a controlled-access model. Under this model, the data will be released to a researcher if access criteria are met. All requests for data sharing should be made to the Co-Principal Investigators who will be responsible for reviewing and granting requests. Requestors should provide a research proposal for review. In the event that a data sharing request is declined, reasons will be provided to the requestor. If the data sharing request is granted, a data-sharing agreement will be initiated by the Co-Principal Investigators alongside the University of Calgary (lead institution). This agreement will include information on the individual data to be shared; if other documents will be available (e.g., statistical codes, data dictionary), when the data will be available and for how long, and how data access will be provided (e.g., file transfer).

Access criteria: The requestor is affiliated with an academic institution as an independent investigator or trainee of an independent investigator; The proposed research question(s) and hypothesis(es) are specific, measurable, and achievable; The proposed research project will be governed/overseen by a local legal/regulatory body; The proposed research project poses no risk of invasion of privacy or breaches of confidentiality for trial participants; A member of the proposed research team has sufficient statistical skills to carry out the proposed analytic plan; The requestor has sufficient financial and/or human resources to see the proposed research project to completion; The proposed research question(s) and hypothesis(es) do not conflict with active or planned studies of the Co-Principal Investigators.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Aug 2028, 52 months after the start.

Of 86 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 52 months is above that.

Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 24, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).Now Located in Canada.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).Now Located in Canada.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06221358
Responsible party
Chad Bousman (Associate Professor, University of Calgary) — Principal investigator
First posted
Jan 24, 2024
Start date
Apr 1, 2024
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Weng-Sam Siu, MSPT, MSc
Contact
sam.siu@ucalgary.ca
5875739747
Madison Heintz, MSW
Contact
psychpgxlab@ucalgary.ca
5875739747
Chad Bousman, MPH, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion